

A critical review of bioactive glasses and glass–ceramics in cancer therapy

Original

A critical review of bioactive glasses and glass–ceramics in cancer therapy / Moeini, A.; Hassanzadeh Chinijani, T.; Malek Khachatourian, A.; Vinicius Lia Fook, M.; Bairo, F.; Montazerian, M.. - In: INTERNATIONAL JOURNAL OF APPLIED GLASS SCIENCE. - ISSN 2041-1286. - ELETTRONICO. - 14:1(2023), pp. 69-87. [10.1111/ijag.16601]

Availability:

This version is available at: 11583/2978612 since: 2023-05-18T14:57:33Z

Publisher:

John Wiley and Sons

Published

DOI:10.1111/ijag.16601

Terms of use:

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

SPECIAL ISSUE ARTICLE

A critical review of bioactive glasses and glass–ceramics in cancer therapy

Ali Moeini¹  | Turan Hassanzadeh Chinijani¹ | Adrine Malek Khachatourian¹  |
Marcus Vinicius Lia Fook² | Francesco Baino³  | Maziar Montazerian² 

¹Department of Materials Science and Engineering, Sharif University of Technology, Tehran, Iran

²Northeastern Laboratory for Evaluation and Development of Biomaterials (CERTBIO), Federal University of Campina Grande, Campina Grande, Paraíba, Brazil

³Institute of Materials Physics and Engineering, Department of Applied Science and Technology, Politecnico di Torino, Torino, Italy

Correspondence

Adrine M. Khachatourian, Department of Materials Science and Engineering, Sharif University of Technology, Tehran, Iran.
Email: khachatourian@sharif.edu

Francesco Baino, Institute of Materials Physics and Engineering, Department of Applied Science and Technology, Politecnico di Torino, Torino, Italy.
Email: francesco.baino@polito.it

Maziar Montazerian, Northeastern Laboratory for Evaluation and Development of Biomaterials (CERTBIO), Federal University of Campina Grande, Campina Grande, PB, Brazil.
Email: maziar_montaz@yahoo.com

Francesco Baino and Maziar Montazerian are members of the American Ceramic Society (ACerS).

Abstract

There is an ongoing profound shift in using glass as a primarily passive material to one that instills active properties. We believe and demonstrate that bioactive glasses (BGs) and glass–ceramics (BGCs) as functional biomaterials for cancer therapy can transform the world of healthcare in the 21st century. Melt/gel-derived BGs and BGCs can carry many exotic elements, including less common rare-earth, and trigger highly efficient anticancer properties via the combination of radiotherapy, photothermal therapy, magnetic hyperthermia, along with drug or therapeutic ions delivery. The addition of these dopants modifies the bioactivity, imparts novel functionalities, and induces specific biological effects that are not achievable using other classes of biomaterials. In this paper, we have briefly reviewed and discussed the current knowledge on promising compositions, processing parameters, and applications of BGs and BGCs in treating cancer. We also envisage the need for further research on this particular, unique class of BGs and BGCs.

KEYWORDS

biomaterial, cancer, glass, glass–ceramic, mesoporous

1 | INTRODUCTION

Cancer is one of the most important reasons for death among the other complex and dangerous diseases that are still largely incurable. However, much progress is being made in this area.¹ Various strategies such as

surgery, chemotherapy, radiotherapy, and new targeted therapies have been developed, including hyperthermia, phototherapy, gas therapy, and intelligent drug delivery to combat cancer and associated complications.² Surgery can successfully treat the disease in the first stages when the cancer cells have not spread over a long distance in

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *International Journal of Applied Glass Science* published by American Ceramic Society and Wiley Periodicals LLC.




FIGURE 1 The different cancer treatments with biomedical glass and glass–ceramics: (A) radiotherapy, (B) drug delivery, (C) phototherapy, and (D) magnetic hyperthermia. (C) *Source:* Adapted from Ref. 14

the body. However, surgery is often not recommended in the later stages of cancer due to its invasive nature.³ Conventional chemotherapy also cannot selectively treat cancer as it does not usually differentiate between cancer and healthy cells. A significant portion of the drugs used in this treatment does not affect the target cancerous tissue but causes unwanted side effects.⁴ Therefore, controlled drug delivery systems are highly recommended. Many other promising methods are introduced for patients who cannot undergo surgery or chemotherapy. These new methods complement basic techniques, are more accurate and effective, and identify and target only tumor cells.⁵

Bioactive glasses (BGs) and glass–ceramics (BGCs) have been introduced since 1969 for various applications in tissue engineering, implantology, and pharmaceuticals because of their exceptional properties such as good biocompatibility, controllable degradation rate, osteoinductivity, antibacterial capability, and pro-angiogenic effect, which are key to develop multifunctional systems.^{6–8} These substances have been highly considered for cancer treatment since the beginning of the 21st century.^{9,10} For this purpose, they are modified by using biologically active and rare elements, increasing their performance range and application.^{11,12} Figure 1 summarizes the different cancer treatment approaches using BGs and BGCs,

including radiotherapy, drug delivery, phototherapy, and hyperthermia.

Radioactive biomedical glasses are already used to kill cancerous cells through the emission of radioactive beta radiation. These glasses are either nonbiodegradable or biodegradable radioactive glasses. Ytria–alumina–silica (YAS) compositional system is one of the most famous nonbiodegradable groups of rare-earth aluminosilicate (REAS) glasses used in brachytherapy, which is an internal radiation therapy with seeded radionuclides inside or in the vicinity of the treatment area. When radionuclides are irradiated, the radioembolization effect significantly reduces blood flow to the cancerous tumor and, hence, reduce the tumor mass. This procedure may complement chemotherapy or surgery (Figure 1A).^{13,14}

Mesoporous bioactive glasses (MBGs) can treat cancerous tumors more purposefully; controlled loading and release of drugs are performed in addition to the inherent properties of glasses, such as the ability to regulate gene expression and regeneration of lost tissue, including bone. Emerging drug delivery systems based on pH-triggered drug release by MBGs are designed to selectively enhance chemotherapy of drugs based on the pH distinction between normal and cancer tissues. These smart-systems provide more toxicity to cancer cells *in vitro* and show selective damage of tumors *in vivo* (Figure 1B).^{15–18}

Various biologically active elements such as copper and bismuth with photothermal (PT) conversion properties have been incorporated in glasses. These glasses in photothermal therapy (PTT) damage cancer cells by absorbing the near-infrared (NIR) light of the laser and converting it into heat. Recent research has shown that heat generation can form reactive nitrogen species (RNS) or reactive oxygen species (ROS) in the patient's body and destroy cancer cells under photodynamic therapy (PDT) or gas therapy (Figure 1C).¹⁹

Magnetic BGCs are another group used to combat cancer. The magnetic phases/crystals are formed within the glassy matrix by controlled heat treatment, resulting in the formation of glass-ceramics. When a magnetic field is applied to these substances, the magnetic phase can generate heat, thus yielding a controlled local increment of the temperature under the treatment mechanism of hyperthermia. This overheating kills cancer cells without damaging healthy cells (Figure 1D).²⁰

In the last few years, enormous progress has been made in developing BGs and BGCs for new and intelligent cancer treatment methods.²¹ As such, the main focus of this article is to snapshot the application of BGs and BGCs in emerging treatment approaches such as radiotherapy, drug delivery, phototherapy, and hyperthermia. The simultaneous use of several treatment methods to maximize therapeutic effect is also highlighted for future research.

2 | RADIOTHERAPY

Unlike chemotherapy and surgery, which are the most typical cancer treatments, radiation is a less invasive strategy that can be applied either from the inside or outside the body. Radiation therapy can destroy tumor cells by damaging the DNA of cancerous cells and losing the competence to divide and proliferate or reduce the size of the malignant mass by applying ionizing radiation as a physical therapeutic agent.^{22,23} Ionizing radiation consists of subatomic particles (photons, protons, and electrons) or electromagnetic waves that have enough energy to ionize atoms or molecules by separating electrons from them.²⁴ In addition to damaging cancerous cells, radiation therapy is sometimes harmful to normal cells. Still, they can keep their functions due to quicker self-repair than neoplastic ones.^{25,26}

There are two strategies for radiation delivery to the injured site. The first case is *ab externo* (from outside the body, external beam radiation is given to the tumor location), which is the most commonly used clinical approach and typically operates with high-energy gamma rays, X-rays, or electrons (provided by a linear accelerator). The second case is *ab interno* using a radioactive source that

delivers internal radiation from inside the body directly to the cancer site.²³ This radioactive source can be left *in situ* indefinitely (permanent brachytherapy) or be terminated and periodically replaced to preserve its therapeutic activity (temporary brachytherapy).²⁷

In brachytherapy, the radioactive sources are immobilized or sealed in microspheres, capsules, seeds, wires, or pellets. The appropriate radioactive sources for brachytherapy are chosen depending on the patient's clinical conditions, disease stage, and physical aspects of radionuclides such as emitted radiation, the half-life time, associated average energy, and the emitted dose rate.²³ The selected radioisotope usually emits beta-ray with a short half-life and high energy or, in a few cases, alpha radiation for cancer treatment.^{28–30} Brachytherapy has been successfully used to treat soft tissue cancer (gynecological and prostate malignant tumors)²³ and osseous tumors (Ewing's sarcoma and metastatic bone cancer).^{23,31,32}

Usually, radioactive seeds for brachytherapy consist of ¹²⁵I as a radioactive element embedded in a metallic capsule (Ti in most cases) (Figure 2A).³³ Still, because of the long half-life of ¹²⁵I (59.5 days), it can be replaced by ⁹⁰Y with a shorter half-life (64.2 h).^{34–36} However, using this metallic capsule may require invasive extra-surgery for its removal.³⁴ Therefore, investigations have been conducted to find new materials to replace radioactive sources.^{36,37} Glasses with particular compositions are good candidates for brachytherapy, which host radionuclides in the glassy matrix. They can be nondegradable or degradable.³⁸ There are also two synthesis methods for radioactive glass fabrication. The first method includes combining the batch material with the radioactive agent and blending them, which causes the radioisotope to become an integral part of the glass. The second method is making radioactive glass from nonradioactive glass (specifically, oxide glasses) by neutron activation. This method is more common than the first one.³⁸ The remarkable point that must be avoided is the generation of some neutron-activated radioisotopes of Ca, K, and Na (the typical ingredients of oxide glasses) with a long half-life of about thousands of years. Also, the biocompatibility and chemical durability of glass matrices are other critical issues that must be considered.^{35,39}

In order to avoid the production of undesirable radioisotopes from highly soluble K and Ca with a long half-life (1.25×10^9 years and 162.7 days, respectively) during neutron activation processes, an REAS system was studied by Day et al. in the early 1980s.^{35,40,41} REAS consists of three oxides ($\text{Al}_2\text{O}_3\text{-SiO}_2\text{-RE}_2\text{O}_3$, where RE_2O_3 is the neutron-activated rare-earth oxide) and is a good candidate for radiotherapy agents due to the fast decay of radioisotope produced during neutron activation processes. Furthermore, these glasses have excellent durability in the biological environment and do not release any




FIGURE 2 (A) A sample of commercial seeds with clinical use for brachytherapy.²⁷ (B) Rods and (C) microspheres made of rare-earth aluminosilicate (REAS) glass in brachytherapy³⁸

radioisotope in vivo. REAS glasses used in brachytherapy have been produced in different shapes like rods (based on the $46.8\text{Sm}_2\text{O}_3\text{-}18.2\text{Al}_2\text{O}_3\text{-}35\text{SiO}_2$ wt% system) (Figure 2B) or microspheres ($55\text{Y}_2\text{O}_3\text{-}20\text{Al}_2\text{O}_3\text{-}25\text{SiO}_2$ wt%) (Figure 2C). REAS includes beta-emitting ^{90}Y (with a half-life of 64.2 h), ^{153}Sm (46.7 h), ^{165}Dy (1.257 min), ^{166}Ho (26.7 h), and $^{186}\text{Re}/^{188}\text{Re}$ (90.6 h/17.0 h). The REAS glasses carrying ^{90}Y or ^{166}Ho present dual functions of avoiding the growth of a tumor and decreasing the mass of the tumor.³⁸

YAS glasses are the most famous family of REAS glasses. These glasses have been synthesized by the flame spheroidization method in the form of microspheres (diameter around 20–30 μm). They kill cancerous cells by simultaneously emitting radiation and performing an embolization effect on the capillaries (radioembolization), which can be used in liver cancer radiotherapy.^{35,36,40,42} YAS glasses containing up to 55-wt% Y_2O_3 have excellent chemical durability. It is also reported that the $40\text{Y}_2\text{O}_3\text{-}20\text{Al}_2\text{O}_3\text{-}40\text{SiO}_2$ (wt%) glass does not release any appreciable amount of ^{90}Y in vivo.⁴⁰ In 1989, the first clinical trial reported by Boos et al. showed a considerably positive outcome in 35 of 46 patients suffering from liver cancer, with a full recovery of 1, a partial recovery of 6, and a disease stability of 24 cases. Furthermore, the mean survival time for the respondent patients was 16.1 months versus 8.8 months for the unresponsive patients.⁴³

In 1999, ^{90}Y -containing glass microspheres, after being endorsed by the Food and Drug Administration, started being commercialized under the TheraSphere brand (Boston Scientific Corporation, Watertown, MA, USA).³⁵ They are currently used to treat patients with primary liver cancer that cannot be removed by surgery (unresectable hepatocellular carcinoma).^{44,45} This product is clinically applied in more than 200 specialized global centers. The microspheres containing ^{90}Y injected into the hepatic artery can be deposited in the capillary bed by radioembolization effect, decreasing the blood flow to the malignant tumor. Then, other follow-up treatments like transplants or surgery with observed a significant reduction of a tumor mass can be performed.^{40,35} In addition, life expectancy has increased in terminal patients from 5–7 months to 12–24 months. Compared to chemotherapy or other cancer therapies, TheraSphere has minor side effects and only causes flu-like symptoms such as mild fever, fatigue, or abdominal pain that may persist in patients after treatment for several days.⁴⁰ In 2006, Bretcanu and Evans provided a comprehensive review of TheraSphere clinical applications for liver cancer treatment.⁴⁶ More recently, Daniel Boyd's team at Dalhousie University, Canada, has developed another radioactive glass that triggers radioembolization and shows promise for treating cancer. This product, trade named Eye90 Microsphere glass, is being commercialized by ABK Biomedical Co.^{47–49}

Recently, it was observed that TheraSphere-based therapy combined with chemotherapy had advantageous effects in selected patients with metastatic colorectal liver cancer. Still, even patients with the chemotherapy-resistant disease received some benefits from the treatment.⁵⁰ Hence, an investigation for assessing the safety and efficacy of TheraSphere radioembolization assisted with second-line therapy was launched in 2018 in patients with metastatic colorectal carcinoma of the liver who had disease advancement during or after first-line cancer chemotherapy. Phase 3 pilot studies have begun at 100 sites in Canada, the USA, Asia, and Europe, and investigation is ongoing.⁵¹

One of the main functions of glasses is their capability to release ions *in vivo*, which can help cell proliferation, gene activation, osteogenesis, or elicit angiogenesis, antibacterial, anti-inflammatory effects, leading to more efficient tissue and bone regeneration. Biodegradability can also be helpful along with the radioactivity of glass. When cancer cells are surgically removed, some small-scale cancer cells that cannot be removed may be left behind and destroyed by the radioactive glass. It is also possible that some tissue or bone may be damaged or removed by surgery, which demands tissue regeneration by bioactivity and ion release properties of BGs.

The critical issue that could not be neglected is the released amount of the therapeutic substance or element from the glass carriers. This issue is truly crucial for biodegradable radioactive glasses as the amount of released radionuclide for brachytherapy must not stimulate the immune system or induce toxic effects in healthy tissues.³⁰

In 2003, Roberto et al. introduced the first radioisotope vectors based on biodegradable glass for therapeutic brachytherapy. In this study, to achieve a similar yield to titanium-encapsulated ¹²⁵I seeds, a group of biphasic materials combined a SiO₂ gel-derived glass with high chemical stability in the biological fluid, and a biodegradable SiO₂-CaO glass carrying neutron-activated ¹⁵³Sm radioisotope was used.⁵² The ¹⁵³Sm radioisotope has a shorter half-life than the ¹²⁵I radioisotope and could operate better in a biodegradable carrier for a short and acceptable duration of several months. However, higher concentrations were used to function comparable with the ¹²⁵I radioisotope.⁴¹ In 2008, Campos et al. also performed X-ray radiographic imaging on ¹⁵³Sm seeds implanted in rabbit liver after 7 months. However, no presences of carrier glass and ¹⁵³Sm seeds were reported, thus confirming the uptake of glass particles into the liver.⁵³ Later, Caccina et al.^{54,55} reported that bioactive silicate glasses exhibited different chemical stability depending on silica content. This type of glass showed good potential as a carrier for their lease of Y₂O₃ in simulated body fluid in brachytherapy. The general rule

is that the more silica in BG, the less chemical solubility is. As a result, glasses with lower silica content have more yttrium release. On the other hand, the presence of yttrium increases the chemical stability of the glass,³⁵ thus allowing a multiple control on glass dissolution kinetics.

Other biodegradable glasses for potential use in brachytherapy include melt-derived alkaline borate and borosilicate glasses. When these glasses are not radioactive anymore, they gradually decompose in the body over hours or weeks.³⁸ For example, during the decomposition of dysprosium-containing lithium-borate (DyLB) glasses, radioisotopes of Dy react with phosphate and calcium in the body fluid and form insoluble phosphates.⁵⁶ In principle, the microspheres react nonuniformly by releasing almost entirely soluble constituents (here B and Li), whereas dysprosium phosphate forms. The initial glass loses up to 80% of its weight after 64 days of implantation. An amount of 10-mg injected glass into a human joint forms only 2 mg of an insoluble dysprosium phosphate-rich reaction product. It is assumed that this low amount will create no tissue damage in humans as the 1-mg injection into the much smaller mice joint did not cause any damage. To date, studies have been performed on borate glass microspheres containing the ¹⁵³Sm, ⁹⁰Y, ¹⁶⁶Ho, ¹⁶⁵Dy, and ¹⁸⁶Re isotopes but have not yet reached the commercialization stage.³⁸ However, more studies are needed to investigate the dissolution mechanism of these glasses to understand their *in vivo* and *in vitro* behaviors.⁵⁶

Nogueira et al.⁵⁷ showed that sol-gel-derived glasses containing radioisotopes of Ba, Zr, and Ho allow better visualization under radiographic imaging due to the additional role of Ba and Zr as contrast agents. Specifically, the glass sample loaded with Ho and Zr showed a significantly better radiological contrast than the sample loaded with only Ho. The presence of Zr also decreases the degradability and bioactivity of glass. ¹⁶⁶Ho-doped glass compared to the Sm-containing one can treat smaller tumors faster due to its higher energy.⁵⁸

Recently, Delpino et al.⁵⁹ examined Ho-doped 58S glass for brachytherapy. The results showed that the Ho content significantly affects the kinetics of the hydrolysis reaction: Specifically, the addition of holmium ions in the glass structure decreased the energy barrier of hydrolysis reactions, thus accelerating glass dissolution in an early stage, whereas the strength of Si-O-Ho bonds yields a more stable dissolution in the long term. Although a high concentration of Ho was added into the glass, most of this dopant remains in the glass structure, thus preventing toxicity. Figure 3 summarizes the structure, *in vitro* bioactivity, and cell culture experiments on 58S gel-glass (60SiO₂-36CaO-4P₂O₅ mol%). It was observed that Ho had no adverse effects on glass bioactivity and can stimulate more preosteoblast cell proliferation as compared to the Ho-free




FIGURE 3 (A) Schematic representation of Ho-doped 58S glass structure, containing silicate tetrahedrons with holmium in octahedral coordination. Water attack possibilities in this glass (right side) should be considered for the chemical stability of Ho (radioactive) ion in the long-term degradation and early-stage dissolution of nonradioactive elements. (B) Osteoblast cell culture experiments on Ho-doped bioactive glass. (C) Results of in vitro apatite forming ability on 2.5-mol% holmium-containing glasses before and after 1 and 14 days immersed in simulated body fluid (SBF) solution confirm the apatite forming ability of this glass⁵⁹

control sample (58S) (Figure 3).⁵⁹ ^{166}Ho -containing BGs produced more radiation to the tumor tissue than other radioisotopes, and the short-range penetration of beta particles is useful to minimize damages to the adjacent healthy tissue.^{60,61}

3 | DRUG AND ION DELIVERY

BGs can act as a powerful local drug delivery system by adsorption, establishing covalent or noncovalent bonds to trap drugs in their cavities.^{62–64} Compared to other biomaterials, BGs can also act as vehicles for the controlled release of ions that can regulate gene expression of cells, which makes them multifunctional candidates in cancer treatment.^{65–69} These carriers show slow and continuous in vitro sustained drug release due to the dissolution of the glass matrix, which is accompanied by ion release as well.⁷⁰

MBGs, first synthesized two decades ago, have become an ideal option in topical and targeted tumor therapies due to their ability to deliver drugs along with various therapeutic elements. Figure 4A illustrates the schematic

preparation of drug-loaded MBGs. Active targeting of MBGs is accomplished by functionalizing their surface by factors such as peptides, antibodies, or proteins.⁷¹ One of the most critical issues in cancer treatment by drug delivery systems is how to differentiate cancer and normal cells and use the differences to achieve a selective and more effective treatment. These dissimilarities include pH differences, redox levels, and expression levels of several enzymes and receptors.^{17,18,72}

The innovative drug delivery systems that have received so much attention are environmental-sensitive carriers.⁷³ They consist of ionizable components (e.g., amines or carboxyl groups), and their structure changes under pH change.⁷⁴ Consequently, the pH gradient will act as the driving force behind the release of the drug from the glass carrier in such systems (Figure 4B: 3 and 4, C).⁷⁴

In some cases, a more finely controlled drug release can be achieved by using pH-sensitive polymer coatings on the surface of glass carriers.⁷⁵ The results demonstrated that these smart systems provided higher toxicity for cancer cells in vitro and showed a selective increase in tumor death in vivo.^{15,75–86} After entering the body, the drug goes through four stages, including absorption, release,




FIGURE 4 (A) Schematic of drug-loaded mesoporous bioactive glass (MBG) preparation. (B) The effect of MBGs on cancer cells and normal cells.¹⁰⁵ Cumulative drug release profile (C) against different pHs and (D) against different drug-loading concentrations⁷⁴

metabolism, and excretion. The drug should be metabolized after entering the body and reaching the target tissue or cell and easily be eliminated from the body after creating the effect.^{87–92}

Specific surface area, composition, pore size, and particle size are among the key factors influencing the rate of glass degradation as well as their biocompatibility in contact with the biological fluid.⁶⁵ On the other hand, drug delivery can be controlled by changing the porosity volume, drug concentration, pH of the environment, and by adding different dopants in the glass structure.^{77,83,85,93–101} Shoaib et al.⁷⁴ studied the effect of drug-loading concentrations and pH for the controlled release of Imatinib (IMT) against cancer cells in MBGs (Figure 4C,D). IMT was loaded with 77.59% efficiency, and its release was affected by the drug-loading concentration (.2–1.0 mg/ml) and the pH of the medium where the release takes place (4.4–10.4). Overall, 81% of IMT was released for 250 h at an acidic pH = 4.4, at 12.19 $\mu\text{g}/\text{ml}$ of IMT-MBG, and significant inhibitory effects were observed on the viability of MG-63 osteosarcoma cancer cells.⁷⁴

It has been proven that hollow spheres of MBGs doped with different ions (Se,⁷⁷ Tb,⁸³ Ag,⁸⁴ Sm,⁸⁵ Ca^{102,103}) have a higher drug-loading capacity and more stable release than dopant-free BGs. Interaction between ions and drugs can synergistically enhance the anticancer effect and improve drug loading.^{98,102} Ur Rahman et al.⁸⁴ reported that Ag-doped MBG nanospheres have higher drug storage capacity and more stable release of doxorubicin (DOX) than the pure MBG nanospheres. It was shown that Ca-MBG nanospheres loaded with DOX could effectively inhibit tumor growth.^{102,103} MBG nanospheres showed continuous and long-term local release of DOX in many studies.^{82,86,104} Hu et al.⁷⁷ studied the cytotoxicity of DOX-Se-MBG and DOX-free nanospheres (Se-MBG) in the context of bone tissue engineering. It was proved that the cytotoxicity of DOX-Se-MBG and Se-MBG nanospheres depends on release time and drug dosage. The viability of MG63 osteosarcoma cells cultured with DOX-Se-MBG nanospheres was slightly higher than the positive control (DOX-free sample), attributed to the interaction between DOX and Se. Indeed, the effect of this synergy apparently seems not so helpful for cancer therapy. However, although Se-MBG nanospheres had a faster inhibitory effect on MG63 osteosarcoma cells in the short term, DOX-Se-MBG nanospheres provided a long-term inhibitory effect on the same cells.⁷⁷

The doping of various elements can influence the microstructural and morphological properties of the MBGs. Ion concentrations can alter drug release due to changes in the number of ionic bindings.^{77,83,85} Also, even the type of ions can affect drug-loading concentrations. For example, doping with Cu and Se^{106,107} was shown to

be associated with drug-loading increase, but Mg, Zn^{106,108} reduced the drug-loading concentration in MBGs structure. The effect on drug-loading capability is related to morphological changes in terms of pore volume, surface area, and pore size of MBGs. For example, the addition of certain amounts of cerium or gallium to $\text{SiO}_2\text{-CaO}$ mesoporous gel-glass modifies the structure, the pore size, and the specific surface area.¹⁰⁹ Furthermore, the addition of metal ions into the structure of MBGs changes the surface charges of nanoparticles, yielding a direct impact on particles aggregation.^{98,110}

Some elements such as Se,^{77,111} Ca,¹¹² Ga,¹¹³ Cu, Ag,^{110,114–116} and Zn¹¹⁷ have shown anticancer properties. Each of these ions exhibits this property via a different mechanism.^{110,118,119} However, the production of ROS—stimulated by such ions—has always been a key factor in developing anticancer properties.¹²⁰

Concentrations of calcium ions in the glass structure can also be effective in drug release and control.^{103,121} Excessive calcium ion release from the glass structure can damage cells and kill them through apoptosis, thus stimulating the anticancer effect.⁹⁸ Released calcium from the glass structure can suppress cancer growth by activating calcium sensor channels on cancer cells with the least damage to healthy cells.¹¹² Ion doping such as Mg and Co provides anticancer properties if these ions are appropriately released from the glass structure properly. This release can be controlled depending on the concentration of dopants and the pH of the release medium.^{75,122} Low and suitable concentrations of cobalt ions can cause angiogenesis during tissue regeneration due to their hypoxia-mimetic effect. If cobalt ion is released rapidly and extensively in situ, this ion can cause the death of cancer cells by ferroptosis.^{120,123–138} Ferroptosis is generally a type of cell death caused by ROS accumulation due to Fenton's or Fenton-like reactions.^{120,139–141} On the other hand, we cannot ignore that cobalt has a potent pro-angiogenic effect, which could contribute to cancer development, thus achieving an opposite effect. Oxidative stress of cells and the production of ROS have been shown to be induced by selenium ions.^{77,111,142} Also, Ga-doped BGs show the ability to suppress cancer cells.¹⁴³

Ferroptosis is a type of programmed cell death dependent on iron and is detected by lipid peroxides accumulation. It is biochemically and genetically different from other types of regulated cell death, like apoptosis. Recently this method attracted significant attention in cancer therapy that kills cancer cells by ROS generation via iron ions-mediated Fenton's reaction. Among ferroptosis-based cancer therapies, metal-containing nanomaterials meddling with ferroptosis cancer therapies efficiently induce ferroptosis of tumor cells without complex cellular signal transduction.¹²⁰ Also, therapeutic metal elements

incorporation into an MBG and controlled release of these soluble therapeutic ions developed MBG with therapeutic properties such as Fe for ferroptosis.¹⁴⁴ The release of Fe ions results in catalytic H_2O_2 decomposition inside the tumor cells and production of ROS, a Fenton's reaction.¹⁴⁵ Fe ions-releasing MBG ultrasmall nanoparticles synthesized by a simple one-pot ultrasonic-coupled sol-gel synthesis can be used as a ferroptosis-based bone cancer treatment. Also, adding 10% Fe_2O_3 to 85SiO₂-15CaO (mol%) glass reduced the particle size and simultaneously increased the specific surface area.¹³⁹

MBGs can also be effective in other cancer treatment methods such as PTT and hyperthermia, depending on the type of ions that they carry.^{110,137}

4 | PHOTOTHERAPY

A laser-irradiated cancerous region could be locally heated in PTT due to the possibility of controlling laser penetration. In this case, overheated cancer cells are killed without harming other organs or tissues. Various nanoparticles have been utilized as PT conversion agents that absorb NIR-light and transform it into heat.¹⁴⁶ The PT effect caused by optical input can also generate the thermal apoptosis of cancerous cells. Studies showed that metal ions doping in the glass structure could provide PT therapeutic ability. Liu et al.⁶⁹ reported the first PT effect in BG doped with copper, iron, manganese, and cobalt ions. Bismuth¹⁴⁷ and carbon dots¹⁴⁸ also induced a PT effect in BGs.

One new idea was to make multifunctional glasses for cancer treatment by combining radiotherapy, drug delivery, and PTT and using BGs to regenerate bone. Multifunctional glasses with anticancer and bone regenerative properties can eliminate bone tumors and often lead to new bone formation to achieve optimal bone tumor therapeutic effect. Wang et al.¹⁴⁷ fabricated Bi-doped BGs for triggering PT and bioactivity response for tissue repair and bone tumor therapy. A Bi-doped BG equips photo-induced hyperthermia and enriched remineralized bone tissue. The high PT transformation of Bi locally raised the temperature from 42 to 86°C depending on the irradiation time and Bi concentration (Figure 5A). The PT effects were managed by controlling the nonradiative and radiative procedures. Also, Bi-doped BGs demonstrated noncytotoxicity before and after laser irradiation and showed an effective inhibitory effect on cancerous cells viability. It was proved that more than 80% of human osteosarcoma line U2OS tumor cells were killed under NIR-light (Figure 5B).¹⁴⁷ Such dual-functional materials exhibit remarkable bioactivity and tumor therapy, offering a new horizon for bone tumor treatment. Copper is another element that can be added to MBGs, giving PT effect, while

maintaining bioactivity. Copper-doped BGs provide good opportunities for biomedical applications due to their excellent biocompatibility, antibacterial properties, bone regenerative potential, and cancer theranostics.¹⁴⁹ In PT, it is critical to apply a very homogeneous laser on the treated area; otherwise, localized hot spots damage the tissues.

Chang et al.¹⁵⁰ synthesized copper-doped MBGs with excellent drug-loading capacity, good bioactivity leading to apatite formation and mineralization, and excellent PT properties. The PT effect could well modulate the drug release, thus allowing a combination of chemotherapy and PTT to enhance tumor eradication.

Another innovative developing method for cancer therapy is gas therapy to generate RNS where adjustable nitric oxide (NO) generation plays a critical role in bone regeneration, combinatory progression of coupled vascularization, and sequential adjuvant tumor ablation. Multifunctional biomaterial system of 2D Nb₂C MXenes wrapped with S-nitrosothiol-grafted mesoporous silica with 3D-printed BG scaffolds showed the specific characteristics of controllable NO release, stimulatory bone regeneration, and highly efficient PT conversion. This multifunctional biomaterial can be coordinated for multitarget ablation of bone tumors to improve localized osteosarcoma treatment due to the NIR-triggered photonic hyperthermia of MXenes in the NIR-II bio window and controlled release of NO.¹⁵¹

5 | MAGNETIC HYPERTHERMIA

Among the mechanisms of tumor cell death induced by the most common thermo-ablation techniques, hyperthermia uses magnetic materials exposed to an external magnetic field to generate a local temperature increase above 42°C. This temperature rise destroys cancer cells without significantly damaging normal tissues.^{146,152} Although various biological effects can simultaneously appear like heat-induced alteration of cell signaling pathways, expression of heat-shock proteins, RNA and DNA alterations, the direct cytotoxic effect of heat, and many other biochemical changes, the precise mechanism of hyperthermia is not yet completely understood.^{153,154} This method is associated with less unfavorable side effects than conventional therapies of various tumors such as glioblastoma, prostate, and metastatic bone cancer. Hyperthermia can be combined with other treatments like PTT, PDT, immunotherapy, gene therapy, chemotherapy (drug delivery), and high-intensity focused ultrasounds.²⁰

Superparamagnetic iron oxide nanoparticles (SPIONs) can significantly reduce or eliminate the population of cancer cells in the patient's body by generating heat due to magnetic hyperthermia. Unlike SPIONs, BGs usually do not exhibit any inherent magnetic behavior unless a




FIGURE 5 (A) Diagram of temperature changes over time for Bi-doped bioactive glass (BG) samples immersed in simulated body fluid (SBF) solution for various irradiation times (at a power density of 1.5 W/cm²). The temperature of S6PyB rises from 42 to 86°C when the concentration of Bi₂O₃ in the glass extends from 1 to 4 mol%. (B) Cell viability of Bi-doped BG before and after laser irradiation (808 nm at 1.5 W/cm² for 5 min)¹⁴⁷

magnetic phase, such as Fe₃O₄, is embedded or somehow nucleated in the glass network (e.g., by thermal treatment), thus obtaining magnetic BGCs.¹⁵⁵ Glass-ceramics generally have better mechanical properties and may also inherit—at least partially—the bioactivity of the parent glass. The magnetic crystalline phases in glass-ceramics cause heat generation when exposed to a magnetic field, helping to kill cancer cells.²⁰ Both melt-derived BGCs and gel-derived mesoporous BGCs with various compositions or dopants were synthesized in order to improve their efficiency for hyperthermia application.¹⁵⁶ It has been shown that MBGs containing iron oxide phase(s) (Fe₃O₄, FeO) are endowed with the double ability of loading/releasing anticancer drugs and eliciting a hyperthermic effect due to the presence of magnetic crystals via ferrimagnetic properties.^{76,78,86,157–159}

Many fabrication techniques like melt-quenching, powder-sintering, and sol-gel, as well as various compositions such as SiO₂-CaO-Fe₂O₃-ZnO,¹⁶⁰ SiO₂-CaO-Na₂O-Fe₂O₃,^{161,162} SiO₂-Na₂O-CaO-P₂O₅-FeO-Fe₂O₃,¹⁶³ SiO₂-CaO-Fe₂O₃-B₂O₃-P₂O₅,¹⁶⁴ SiO₂-Fe₂O₃-Li₂O-CaO-MnO-P₂O₅,¹⁶⁵ SiO₂-CaO-P₂O₅-MgO-MnO₂-Fe₂O₃,¹⁶⁶ SiO₂-CaO-P₂O₅-Fe₂O₃-ZnO-Na₂O,^{167–169} and SiO₂-CaO-P₂O₅-MgO-CaF₂-MnO₂-Fe₂O₃^{170–172} were investigated so far for hyperthermia.

Fabrication methods, sintering temperature, crystallization,^{173,174} synthesis atmosphere,¹⁷⁵ additives,^{176,177} and dopants^{159,178} are important parameters that affect the structural, magnetic and biological properties of BGs and BGCs. Apart from the conventional fabrication methods,

new techniques like the sol-gel method, electrospinning, and 3D printing were also developed to improve the properties of BGs and BGCs. More reactive materials in a wider compositional range are obtained by the sol-gel method as compared to the traditional melt-quenching route due to the unique textural properties (e.g., inherent nano-porosity) that directly derives from the sol-gel synthesis process.^{179–181} However, nucleation and crystallization in sol-gel BGs are more complex and difficult to control compared to melt-derived systems.¹⁸²

BG fibers (BGFs), mainly fabricated by the electrospinning method, have potential biomedical applications due to their unique fibrous structure, resembling the structure of fibrin clots. Fe-doped mesoporous BGFs (Fe-MBGFs) fabricated by this method has a weak coercive field and a narrow hysteresis loop. The magnetic property of Fe-MBGFs can be enhanced by more iron salt precipitation into the porous polystyrene fiber template. Multifunctional scaffolds with hyperthermia and local drug delivery functions were constructed from these Fe-MBGFs for bone defects therapy.¹⁸³

Magnetic composite scaffolds were fabricated by Dittler et al.,¹⁸⁴ who coated a foam-derived 45S5 Bioglass structure with iron-doped hydroxyapatite (Fe-HA) nanoparticles. This magnetic 3D Fe-HA-BG scaffold has potential application in biology and nanomedicine as contrast agents for magnetic resonance imaging, drug carriers, and magnetic hyperthermia applications.¹⁸⁴

Multifunctional systems can be fabricated by utilizing 3D printing of scaffolds with glass and magnetic

particles. Zhang et al.¹⁸⁵ studied a 3D-printed multi-functional Fe₃O₄/MBG/PCL scaffolds with hierarchically meso-macropore architecture and uniform pore size and shape. These scaffolds exhibited sustained anticancer drug delivery, superior apatite-forming ability (bioactivity), and magnetic heating properties due to the presence of Fe₃O₄ nanoparticles. Fe₃O₄ nanoparticles incorporated into the MBG/PCL scaffolds were also beneficial in stimulating the differentiation and proliferation of h-BMSCs.¹⁸⁵

Li et al.¹⁸⁶ proposed a novel magnetic BGC utilizing graphite-modified magnetite with improved magnetic property. Graphite-modified Fe₃O₄ was incorporated into the BGC via a sol-gel technique and then optimized sintering and quenching procedures enhanced the magnetic properties of the system.

As mentioned earlier, the sintering temperature also affects the properties of glass-ceramics. In SrFe₁₂O₁₉-P₂O₅-CaO-Na₂O BGCs, the coercivity of the material increases, and the SrFe₁₂O₁₉ crystallite size decreases, respectively, as sintering temperature raises. At the minimum sintering temperature (500°C), SrFe₁₂O₁₉ phase with the largest crystallite size and highest crystallinity was observed, along with the highest saturation magnetization (M_s), and remanent magnetization (M_r).¹⁷³

Another critical parameter to be taken into account during the fabrication of BGs and BGCs is the control of the atmosphere. Hou et al. investigated the effect of the treatment atmosphere on the magnetic properties of CaO-Al₂O₃-SiO₂-Fe₃O₄ glass-ceramics prepared by the powder-sintering method. The magnetic properties of glass-ceramics could be tuned by varying the ratio of Fe³⁺ to Fe²⁺, which was modified by changing the oxygen partial pressure in the melting process. The air atmosphere during heat treatment causes Fe₂O₃ (hematite) precipitation. On the contrary, using an inert atmosphere such as an argon atmosphere can reduce the amount of oxygen and favor the formation of magnetite.¹⁷⁵ The same authors reported that an increment of heat-treatment temperature decreased the saturation magnetization and remanent magnetization, which was attributed to the reduction of magnetite content because of the remelting of magnetite crystals into the glass matrix at a higher temperature.

Similar conclusions about the effect of the heat-treatment atmosphere (argon vs. air) were also reported by Baino et al., who synthesized Fe-doped silicate glasses and glass-ceramics by the sol-gel method.¹⁵⁶

It was also proven that three main phases of iron oxide (magnetite, hematite, and maghemite) show superparamagnetic properties at the nanoscale. The crystallinity of the hematite phase was affected by the content of iron oxide in the glass-ceramic composition. However, the final hematite crystal size was not affected by iron oxide content.¹⁸⁷ Also, adding P₂O₅ to magnetic Fe₂O₃-CaO-

SiO₂ glass-ceramics promoted the formation of a surface apatite layer (bioactivity) while eliciting low cytotoxicity in vitro.¹⁸⁸

Mesoporous lithium-ferrite-containing BGs synthesized through the sol-gel technique are another class of promising BGs for hyperthermia. Yazdanpanah et al.¹⁸⁹ proved that these glasses are appropriate for use as thermoseeds. The magnetic properties of samples were improved when the content of magnetic crystals increased, and a local temperature of 47.2°C could be reached under hyperthermic effect.

Koohkan et al.¹⁹⁰ synthesized copper-containing MBGs for hyperthermia in bone defect treatment. The addition of copper oxide in Fe-doped BGs increased the magnetic saturation of the sample and improved superparamagnetic behaviors. The presence of copper in the magnetic glass structure caused further calcium release and improved bioactivity. In addition, Fe/Cu-containing MBGs can be used as a multifunctional system combining hyperthermia, therapeutic ion release, and drug delivery. The antibacterial properties of Fe-BG and Cu-BG were also found to be better than those of Fe-Cu-BG.¹⁹⁰

The gradual replacement of B₂O₃ with SiO₂ in a magnetic 20BaO-20Fe₂O₃-xSiO₂-(60-x)B₂O₃-1CeO₂ glass-ceramic with various compositions ($x = 0-50$ wt%) changed the types of crystalline phases that nucleated in the material, that is, Fe₂O₃, Ba₄B₂O₇, BaFe₂O₄, and Fe₃O₄. As a result of this gradual replacement, a “boron abnormal phenomenon” was observed due to the different [BO₃]/[BO₄] ratios in the glass-ceramics composition, which led to a continuous transition from the paramagnetic to the ferromagnetic behavior when x increased from 20 to 30 wt%, accompanied by a significant increase of the saturation magnetization.¹⁹¹

Glass-ceramic engineering provides versatile flexibility in hyperthermia. It is possible to enhance the magnetic properties or generate heat by developing finely nanostructured glass-ceramic. Shah et al.¹⁶⁷ synthesized nano-sized ZnFe₂O₄ crystallites with pseudo-single domain structures formed in ferromagnetic zinc/ferrite-containing glass-ceramics by aligning magnetic field.

Some of the most recent studies have focused on the association of hyperthermia with chemotherapy to limit the well-known side effects of chemotherapy. Local heating of tumors increases the sensitivity of malignant cells to drugs, thus allowing a reduction of the drug's dosage and the side effects on the human body.¹⁹² Sometimes a polymeric additive can be used in the system so that the desired drugs can be embedded in this component. When the magnetic field is applied and the system heats up, the polymer component melts, and the drug is released in a controlled way.¹⁹³ Magnetite (Fe₃O₄)-containing MBGs also creates synergy for treating cancer by hyperthermia




FIGURE 6 Combining magnetic hyperthermia with chemotherapy or photothermal therapy (PTT) enhances cancer treatment efficacy

and concurrent drug delivery, adding value to stimulating bone regeneration.¹⁹⁴

Another approach to enhance BG properties relies on the design and production of composite materials.^{195–197} Tripathi et al.¹⁹⁸ combined strontium-containing BG (46.1SiO₂–21.9CaO–24.4Na₂O–2.6P₂O₅–5SrO wt%) with manganese ferrite (MnFe₂O₄) to obtain a dual-phase magnetic composite with enhanced biocompatibility and antimicrobial properties. The results showed that this composite had an antibacterial effect on both Gram-positive (*Staphylococcus aureus*) and Gram-negative (*Escherichia coli*) bacteria while exhibiting superparamagnetic characteristics and heating capability for potential use in hyperthermia application.¹⁹⁸ In another study, Bruno et al.¹⁹⁹ have dispersed a ferrimagnetic BGC in a poly(methyl methacrylate) matrix, thus obtaining a composite cement. The glass–ceramic contained magnetite crystals embedded in an amorphous bioactive SiO₂–Na₂O–CaO–P₂O₅–FeO–Fe₂O₃ matrix. The material was recommended as an injectable bone filler for treating osseous tumors by hyperthermia.¹⁹⁹ In vitro properties of this composite bone cement were investigated, and a synergistic effect between bioactivity and cell mineralization was observed, that is, cells seemed to be stimulated in their mineralization process by the ions released from the BGC particles even at the early stages of culture (72 h).²⁰⁰

Among the methods described, new treatments have emerged that lead to new substances in the treatment and control of cancer. Developing BGs and BGCs containing two or more therapeutic approaches such as magnetic, drug-release ability, PT, and radioactive properties is a

hot spot zone for future research. There is consent that the immense promise comes when multiple therapeutic actions against cancer are activated simultaneously. For example, Figure 6 shows that magnetic hyperthermia can synergistically combine with chemotherapy and PTT.

6 | CONCLUSIONS AND PERSPECTIVES

It has been demonstrated that BGs developed 50 years ago are increasingly researched for cancer therapy and tissue engineering. It is also believed that MBGs are novel systems within the BG family that can stimulate multiple therapeutic actions, thanks to their unique composition, easy-to-functionalize nature, and tailorable textural properties such as large surface area, pore sizes, and pore volumes. They are promising platforms that can offer simultaneous controlled drug delivery, tissue regeneration, PT therapy, and hyperthermia. BGCs are also remarkable in terms of having higher mechanical strength and magnetic properties.²⁰¹ Today, nanocomposite or hybrid materials that combine biodegradability and bioactivity are extensively researched for 3D bioprinting and tissue engineering. Composite bio-inks incorporating “anti-cancer BGs” permit the development of scaffolds that can replace the resected cancerous tissue (commonly bone). They can regenerate tissue and inhibit the recurrence of cancer. They can even contribute to 4D bioprinting, where time, pH, or biological parameters are integrated with 3D bioprinting as the fourth dimension. In this regard, BGs can change their functionalities when an external stimulus

like pH is imposed or when cell fusion or specific chemical reactions occur. This interesting and emerging research field demands further attention and multidisciplinary collaboration of bio-glass communities with other fields.

Future research is envisaged in which theoretical and computational modeling can significantly accelerate the compositional and microstructural design, characterization, synthesis, and application of materials.^{202–204} In the last 25 years, more than 6000 articles and 100 review papers have highlighted the impact of the discovery of BGs on the pathways of biomaterials research. We applaud these very accurate portrayals of the early days after the discovery of Bio-glass by Larry Hench in 1969, the chronology, numerous advances, and future challenges. However, as the literature became rich in this topic, few works have addressed data/model-driven approaches to designing new BGs or efficiently predicting their properties. This task should be accelerated as a critical part of the macro-endeavor to decode the “glass genome”.²⁰⁵ Montazerian et al.²⁰⁶ have recently reviewed all publications that have applied molecular dynamics simulations, machine learning approaches, and meta-analysis for understanding BGs. They argued that more modeling of BGs should be employed to design specific properties of glass, including anticancer properties, in the future. It is more complicated but indispensable to model the therapeutic action of BGs, which should focus on modeling the biological response of this biomaterial after implantation and its ability to influence processes such as cell proliferation, cell adhesion, protein adsorption, angiogenesis, osteogenesis, bactericidal effects, and anticancer properties.

ACKNOWLEDGMENT

We would like to thank Omid Sedighi and Amirhossein Alaghmandfard for preparing Figure 6.

Open Access Funding provided by Politecnico di Torino within the CRUI-CARE Agreement.

ORCID

Ali Moeini  <https://orcid.org/0000-0003-2748-8141>

Adrine Malek Khachatourian  <https://orcid.org/0000-0001-7173-2178>

Francesco Baino  <https://orcid.org/0000-0001-8860-0497>

Maziar Montazerian  <https://orcid.org/0000-0002-1409-9182>

REFERENCES

- Ashrafzadeh M, Najafi M, Makvandi P, Zarrabi A, Farkhondeh T, Samarghandian S. Versatile role of curcumin and its derivatives in lung cancer therapy. *J Cell Physiol.* 2020;235(12):9241–68.
- Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, Zahmatkeshan M, Tavakol S, Makvandi P, et al. In vivo gene delivery mediated by non-viral vectors for cancer therapy. *J Control Release.* 2020;325:249–75.
- Moghaddam FD, Akbarzadeh I, Marzbankia E, Farid M, Khaledi L, Hossein Reihani A, et al. Delivery of melittin-loaded niosomes for breast cancer treatment: an in vitro and in vivo evaluation of anti-cancer effect. *Cancer Nanotechnol.* 2021;12(1):1–35.
- Ashrafzadeh M, Hushmandi K, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, et al. Progress in delivery of siRNA-based therapeutics employing nano-vehicles for treatment of prostate cancer. *Bioengineering.* 2020;7(3):91.
- Ashrafzadeh M, Bakhoda MR, Bahmanpour Z, Ilkhani K, Zarrabi A, Makvandi P, et al. Apigenin as tumor suppressor in cancers: biotherapeutic activity, nanodelivery, and mechanisms with emphasis on pancreatic cancer. *Front Chem.* 2020;8:829.
- Montazerian M, Zanotto ED. A guided walk through Larry Hench's monumental discoveries. *J Mater Sci.* 2017;52(15):8695–732.
- Montazerian M, Zanotto ED. Bioactive glass-ceramics: processing, properties and applications. In: *Bioactive glasses: fundamentals, technology and applications.* London: Royal Society of Chemistry; 2016. p. 27–60.
- Boccaccini AR, Brauer DS, Hupa L. *Bioactive glasses: fundamentals, technology and applications.* London: Royal Society of Chemistry; 2016.
- Baino F, Hamzehlou S, Kargozar S. Bioactive glasses: where are we and where are we going?. *J Funct Biomater.* 2018;9(1):25.
- Kargozar S, Baino F, Hamzehlou S, Hill RG, Mozafari M. Bioactive glasses entering the mainstream. *Drug Discov Today.* 2018;23(10):1700–4.
- Perić Kačarević Ž, Rider P, Alkildani S, Retnasingh S, Pejakić M, Schnettler R, et al. An introduction to bone tissue engineering. *Int J Artif Organs.* 2020;43(2):69–86.
- Pantulap U, Arango-Ospina M, Boccaccini AR. Bioactive glasses incorporating less-common ions to improve biological and physical properties. *J Mater Sci – Mater Med.* 2022;33(1):1–41.
- Baino F, Fiume E, Ciavattini S, Kargozar S, Borges R, Genova LA, et al. Biomedical radioactive glasses for brachytherapy. *Materials (Basel).* 2021;14(5):1131.
- Liao J, Han R, Wu Y, Qian Z. Review of a new bone tumor therapy strategy based on bifunctional biomaterials. *Bone Res.* 2021;9(1):1–13.
- Shoib M, Bahadur A, Iqbal S, Al-Anazy MM, Laref A, Tahir MA, et al. Magnesium doped mesoporous bioactive glass nanoparticles: a promising material for apatite formation and mitomycin c delivery to the MG-63 cancer cells. *J Alloys Compd.* 2021;866:159013.
- Zhang X, Li X-W, Li J-G, Sun X-D. Preparation and characterizations of bioglass ceramic cement/Ca-P coating on pure magnesium for biomedical applications. *ACS Appl Mater Interfaces.* 2014;6(1):513–25.
- Shi Z, Li Q, Mei L. pH-Sensitive nanoscale materials as robust drug delivery systems for cancer therapy. *Chin Chem Lett.* 2020;31(6):1345–56.
- Li Li, Yang Wu-W, Xu D-G. Stimuli-responsive nanoscale drug delivery systems for cancer therapy. *J Drug Target.* 2019;27(4):423–33.

19. Huang Z, Tian Z, Zhu M, Wu C, Zhu Y. Recent Advances in biomaterial scaffolds for integrative tumor therapy and bone regeneration. *Adv Ther.* 2021;4(3):2000212.
20. Sedighi O, Alaghmandfard A, Montazerian M, Bairo F. A critical review of bioceramics for magnetic hyperthermia. *J Am Ceram Soc.* 2022;105(3):1723–47.
21. Montazerian M, Singh SP, Zanutto ED. An analysis of glass-ceramic research and commercialization. *Am Ceram Soc Bull.* 2015;94(4):30–5.
22. Pontieri GM, Russo MA, Frati LP. *Generale*. 4th ed. Padova, Italy: Piccin Editore; 2009.
23. Baskar R, Lee KA, Yeo R, Yeoh K-W. Cancer and radiation therapy: current advances and future directions. *Int J Med Sci.* 2012;9(3):193.
24. Ryan JL. Ionizing radiation: the good, the bad, and the ugly. *J Invest Dermatol.* 2012;132(3):985–93.
25. Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. *Nat Rev Cancer.* 2011;11(4):239–53.
26. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. *Nature.* 2009;461(7267):1071–8.
27. I-125 Seeds. Available online: <https://www.eyephysics.com/PS/PS6/UserGuide/OrderSeeds.html>. Accessed 17 June 2022.
28. Poty S, Francesconi LC, Mcdevitt MR, Morris MJ, Lewis JS. α -Emitters for radiotherapy: from basic radiochemistry to clinical studies—Part 1. *J Nucl Med.* 2018;59(6):878–84.
29. Arazi L, Cooks T, Schmidt M, Popovtzer A, Rosenfeld E, Mizrahi A, et al. Alpha DaRT: revolutionary alpha-emitters brachytherapy. *J Med Imaging Radiat Sci.* 2019;50(4):S96–7.
30. Domankevich V, Cohen A, Efrati M, Schmidt M, Rammensee H-G, Nair SS, et al. Combining alpha radiation-based brachytherapy with immunomodulators promotes complete tumor regression in mice via tumor-specific long-term immune response. *Cancer Immunol Immunother.* 2019;68(12):1949–58.
31. Feng S, Wang Li, Xiao Z, Maharjan R, Chuanxing Li, Fujun Z, et al. 125I seed implant brachytherapy for painful bone metastases after failure of external beam radiation therapy. *Medicine (Baltimore).* 2015;94(31):e1253.
32. Radiation Therapy for Bone Cancer. Available online: <https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/radiation.html>. Accessed 13 December 2020.
33. Goudreau SH, Joseph JP, Seiler SJ. Preoperative radioactive seed localization for nonpalpable breast lesions: technique, pitfalls, and solutions. *Radiographics.* 2015;35(5):1319–34.
34. Richmond CR, Findlay JS. Half-life of iodine-125. *Health Phys.* 1966;12(6):865.
35. Hench LL, Day DE, Höland W, Rheinberger VM. Glass and medicine. *Int J Appl Glass Sci.* 2010;1(1):104–17.
36. Christie JK, Malik J, Tilocca A. Bioactive glasses as potential radioisotope vectors for in situ cancer therapy: investigating the structural effects of yttrium. *Phys Chem Chem Phys.* 2011;13(39):17749–55.
37. Rahaman MN, Day DE, Sonny Bal B, Fu Q, Jung SB, Bonewald LF, Tomsia AP. Bioactive glass in tissue engineering. *Acta Biomater.* 2011;7(6):2355–73.
38. Day DE. Glasses for radiotherapy. In: Jones JR, Clare AG, editors. *Bio-glasses: an introduction*. 1st ed. vol. 13. Hoboken, NJ: John Wiley & Sons; 2012. p. 203–28.
39. Tan HY, Yeong CH, Wong YH, McKenzie M, Kasbollah A, Md. Shah MN, et al. Neutron-activated theranostic radionuclides for nuclear medicine. *Nucl Med Biol.* 2020;90–91:55–68.
40. White JE, Day DE. Rare earth aluminosilicate glasses for in vivo radiation delivery. *Key Eng Mater.* 1994;94:181–208.
41. Lin Y, Mauro JC, Kaur G. Bioactive glasses for cancer therapy. In: *Biomedical, therapeutic and clinical applications of bioactive glasses*. Amsterdam: Elsevier; 2019. p. 273–312.
42. Day DE, Ehrhardt GJ. *Glass microspheres US 4789501 A*. Columbia, MO: Univ. Missouri Syst.; 1988.
43. Boos G, Thirwell M, Blanchard R, Crypys C, Herba M, Gonzales L, et al. Y-radioactive glasses for treatment of liver cancer. In: *Proceedings of the 25th annual meeting of the American Society Clinical Oncology*, San Francisco, CA, USA; 1989. p. 21–3.
44. Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery. Available online: <https://clinicaltrials.gov/ct2/show/NCT00039078>. Accessed on 1 December 2021.
45. Carr BI. Hepatic arterial 90yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. *Liver Transpl.* 2004;10(S2):S107–10.
46. Bretcanu O, Evans I. Glasses for treatment of liver cancer by radioembolization. In: *Biocompatible glasses*. Cham: Springer; 2016. p. 267–83.
47. Henry EC, Mawko G, Tonkopi E, Frampton J, Kehoe S, Boyd D, et al. Quantification of the inherent radiopacity of glass microspheres for precision dosimetry in yttrium-90 radioembolization. *Biomed Phys Eng Express.* 2019;5(5):055011.
48. Henry EC, Strugari M, Mawko G, Brewer KD, Abraham R, Kappadath SC, et al. Post-administration dosimetry in yttrium-90 radioembolization through micro-CT imaging of radiopaque microspheres in a porcine renal model. *Phys Med Biol.* 2021;66(9):095011.
49. Henry EC, Strugari M, Mawko G, Brewer K, Liu D, Gordon AC, et al. Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model. *EJNMMI Phys.* 2022;9:21.
50. Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, et al. Outcomes of therasphere radioembolization for colorectal metastases. *Clin Colorectal Cancer.* 2015;14(3):146–53.
51. Chauhan N, Mulcahy MF, Salem R, Benson Iii AIB, Boucher E, Bukovcan J, et al. Therasphere yttrium-90 glass microspheres combined with chemotherapy versus chemotherapy alone in second-line treatment of patients with metastatic colorectal carcinoma of the liver: protocol for the EPOCH phase 3 randomized clinical trial. *JMIR Res Protoc.* 2019;8(1):e11545.
52. Roberto WDS, Pereira MM, Campos TPRDe. Analysis of bioactive glasses obtained by sol-gel processing for radioactive implants. *Mater Res.* 2003;6:123–7.
53. Campos TPR, Andrade JPL, Costa IT, Silva CHT. Study of the Sm-153 seeds degradation and evaluation of the absorbed dose in rabbit's liver implants. *Prog Nucl Energy.* 2008;50(7):757–66.
54. Cacaina D, Ylänen H, Hupa M, Simon S. Study of yttrium containing bioactive glasses behaviour in simulated body fluid. *J Mater Sci – Mater Med.* 2006;17(8):709–16.
55. Cacaina D, Ylänen H, Simon S, Hupa M. The behaviour of selected yttrium containing bioactive glass microspheres

- in simulated body environments. *J Mater Sci – Mater Med.* 2008;19(3):1225–33.
56. Conzone SD, Brown RF, Day DE, Ehrhardt GJ. In vitro and in vivo dissolution behavior of a dysprosium lithium borate glass designed for the radiation synovectomy treatment of rheumatoid arthritis. *J Biomed Mater Res.* 2002;60(2):260–8.
 57. Nogueira LB, Campos TPR. Nuclear characterization of radioactive bioglass seed for brachytherapy studies. *M&C 2011: International conference on mathematics and computational methods applied to nuclear science and engineering, Brazil.* 2011.
 58. Nogueira LB, Campos TPR. Synthesis, chemical characterization and radiological response of Ho and HoZr bioglass seeds. *J Sol-Gel Sci Technol.* 2016;77(3):688–98.
 59. Delpino GP, Borges R, Zambanini T, Joca JFS, Gaubeur I, De Souza ACS, et al. Sol-gel-derived 58S bioactive glass containing holmium aiming brachytherapy applications: a dissolution, bioactivity, and cytotoxicity study. *Mater Sci Eng, C.* 2021;119:111595.
 60. Hosseini SH, Enferadi M, Sadeghi M. Dosimetric aspects of 166Ho brachytherapy biodegradable glass seed. *Appl Radiat Isot.* 2013;73:109–15.
 61. Khorshidi A, Ahmadinejad M, Hamed Hosseini S. Evaluation of a proposed biodegradable 188Re source for brachytherapy application: a review of dosimetric parameters. *Medicine (Baltimore).* 2015;94(28):e1098.
 62. Zhu M, Zhang L, He Q, Zhao J, Limin G, Shi J. Mesoporous bioactive glass-coated poly (L-lactic acid) scaffolds: a sustained antibiotic drug release system for bone repairing. *J Mater Chem.* 2011;21(4):1064–72.
 63. Zhu Y, Kaskel S. Comparison of the in vitro bioactivity and drug release property of mesoporous bioactive glasses (MBGs) and bioactive glasses (BGs) scaffolds. *Microporous Mesoporous Mater.* 2009;118(1–3):176–82.
 64. López-Noriega A, Arcos D, Vallet-Regí M. Functionalizing mesoporous bioglasses for long-term anti-osteoporotic drug delivery. *Chem Eur J.* 2010;16(35):10879–86.
 65. Postler A, Lützner C, Beyer F, Tille E, Lützner J. Analysis of total knee arthroplasty revision causes. *BMC Musculoskelet Disord.* 2018;19(1):1–6.
 66. Leite AJ, Sarker B, Zehnder T, Silva R, Mano JF, Boccaccini AR. Bioplotting of a bioactive alginate dialdehyde-gelatin composite hydrogel containing bioactive glass nanoparticles. *Biofabrication.* 2016;8(3):035005.
 67. Rottensteiner-Brandl U, Detsch R, Sarker B, Lingens L, Köhn K, Kneser U, et al. Encapsulation of rat bone marrow derived mesenchymal stem cells in alginate dialdehyde/gelatin microbeads with and without nanoscaled bioactive glass for in vivo bone tissue engineering. *Materials (Basel).* 2018;11(10):1880.
 68. Liu Y, Lin R, Ma L, Zhuang H, Feng C, Chang J, et al. Mesoporous bioactive glass for synergistic therapy of tumor and regeneration of bone tissue. *Appl Mater Today.* 2020;19:100578.
 69. Liu Y, Li T, Ma H, Zhai D, Deng C, Wang J, et al. 3D-printed scaffolds with bioactive elements-induced photothermal effect for bone tumor therapy. *Acta Biomater.* 2018;73:531–46.
 70. El-Kady AM, Farag MM. Bioactive glass nanoparticles as a new delivery system for sustained 5-fluorouracil release: characterization and evaluation of drug release mechanism. *J Nanomater.* 2015;2015:1–11.
 71. Barui AK, Oh JY, Jana B, Kim C, Ryu J. Cancer-targeted nanomedicine: overcoming the barrier of the protein corona. *Adv Ther.* 2020;3(1):1900124.
 72. Felber AE, Dufresne M-H, Leroux J-C. pH-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. *Adv Drug Deliv Rev.* 2012;64(11):979–92.
 73. Zeng X, Liu G, Tao W, Ma Y, Zhang X, He F, et al. A drug-self-gated mesoporous antitumor nanoplatfrom based on pH-sensitive dynamic covalent bond. *Adv Funct Mater.* 2017;27(11):1605985.
 74. Shoaib M, Saeed A, Ur Rahman MS, Naseer MM. Mesoporous nano-bioglass designed for the release of imatinib and in vitro inhibitory effects on cancer cells. *Mater Sci Eng, C.* 2017;77:725–30.
 75. Li X, Zhang Xu, Zhao Y, Sun L. Fabrication of biodegradable Mn-doped mesoporous silica nanoparticles for pH/redox dual response drug delivery. *J Inorg Biochem.* 2020;202:110887.
 76. Tran VyA, Vo VG, Shim K, Lee S-W, An SSA. Multimodal mesoporous silica nanocarriers for dual stimuli-responsive drug release and excellent photothermal ablation of cancer cells. *Int J Nanomedicine.* 2020;15:7667–85.
 77. Hu M, Fang J, Zhang Y, Wang X, Zhong W, Zhou Z. Design and evaluation a kind of functional biomaterial for bone tissue engineering: selenium/mesoporous bioactive glass nanospheres. *J Colloid Interface Sci.* 2020;579:654–66.
 78. Ur Rahman MS, Tahir MA, Noreen S, Yasir M, Ahmad I, Khan MB, et al. Magnetic mesoporous bioactive glass for synergetic use in bone regeneration, hyperthermia treatment, and controlled drug delivery. *RSC Adv.* 2020;10(36):21413–9.
 79. Nawaz Q, Fuentes-Chandía M, Tharmalingam V, Ur Rehman MA, Leal-Egafía A, Boccaccini AR. Silibinin releasing mesoporous bioactive glass nanoparticles with potential for breast cancer therapy. *Ceram Int.* 2020;46(18):29111–9.
 80. Wang B, Meng W, Bi M, Ni Y, Cai Q, Wang J. Uniform magnesium silicate hollow spheres as high drug-loading nanocarriers for cancer therapy with low systemic toxicity. *Dalton Trans.* 2013;42(24):8918–25.
 81. Muhammad F, Guo M, Qi W, Sun F, Wang A, Guo Y, et al. pH-triggered controlled drug release from mesoporous silica nanoparticles via intracellular dissolution of ZnO nanolids. *J Am Chem Soc.* 2011;133(23):8778–81.
 82. Wu C, Fan W, Chang J. Functional mesoporous bioactive glass nanospheres: synthesis, high loading efficiency, controllable delivery of doxorubicin and inhibitory effect on bone cancer cells. *J Mater Chem B.* 2013;1(21):2710–8.
 83. Wang X, Zhang Y, Lin C, Zhong W. Sol-gel derived terbium-containing mesoporous bioactive glasses nanospheres: in vitro hydroxyapatite formation and drug delivery. *Colloids Surfaces B Biointerfaces.* 2017;160:406–15.
 84. Ur Rahman MS, Tahir MA, Noreen S, Yasir M, Khan MB, Mahmood T, et al. Osteogenic silver oxide doped mesoporous bioactive glass for controlled release of doxorubicin against bone cancer cell line (MG-63): in vitro and in vivo cytotoxicity evaluation. *Ceram Int.* 2020;46(8):10765–70.
 85. Zhang Y, Wang X, Su Y, Chen D, Zhong W. A doxorubicin delivery system: samarium/mesoporous bioactive

- glass/alginate composite microspheres. *Mater Sci Eng, C*. 2016;67:205–13.
86. Sabouri Z, Labbaf S, Karimzadeh F, Baharlou-Houreh A, Mcfarlane TV, Esfahani MHN. Fe₃O₄/bioactive glass nanostructure: a promising therapeutic platform for osteosarcoma treatment. *Biomed Mater*. 2021;16(3):035016.
 87. Sokolovskaya E, Rahmani S, Misra AC, Bräse S, Lahann J. Dual-stimuli-responsive microparticles. *ACS Appl Mater Interfaces*. 2015;7(18):9744–51.
 88. Zhou L, Wang H, Li Y. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance. *Theranostics*. 2018;8(4):1059–74.
 89. Duncan R. Polymer therapeutics at a crossroads? Finding the path for improved translation in the twenty-first century. *J Drug Target*. 2017;25(9–10):759–80.
 90. Deng Li, Ren J, Li J, Leng J, Qu Y, Lin C, Shi D. Magnetically responsive star-block copolymeric micelles for controlled drug delivery and enhanced thermo-chemotherapy. *Nanoscale*. 2015;7(21):9655–63.
 91. Wu Y, Chen W, Meng F, Wang Z, Cheng Ru, Deng C, et al. Core-crosslinked pH-sensitive degradable micelles: a promising approach to resolve the extracellular stability versus intracellular drug release dilemma. *J Control Release*. 2012;164(3):338–45.
 92. Nowag S, Haag R. pH-responsive micro-and nanocarrier systems. *Angew Chem Int Ed*. 2014;53(1):49–51.
 93. Asefa T, Tao Z. Biocompatibility of mesoporous silica nanoparticles. *Chem Res Toxicol*. 2012;25(11):2265–84.
 94. Popat A, Liu J, Lu GQ(M), Qiao SZ. A pH-responsive drug delivery system based on chitosan coated mesoporous silica nanoparticles. *J Mater Chem*. 2012;22(22):11173–8.
 95. Gianluca M, Erika F, Gigliola L, Valentina A, Francesca F, Claudio M, et al. The role of coordination chemistry in the development of innovative gallium-based bioceramics: the case of curcumin. *J Mater Chem*. 2011;21(13):5027–37.
 96. Nandiyanto ABD, Kim S-G, Iskandar F, Okuyama K. Synthesis of spherical mesoporous silica nanoparticles with nanometer-size controllable pores and outer diameters. *Microporous Mesoporous Mater*. 2009;120(3):447–53.
 97. Lin Yu-S, Haynes CL. Synthesis and characterization of biocompatible and size-tunable multifunctional porous silica nanoparticles. *Chem Mater*. 2009;21(17):3979–86.
 98. Zheng K, Boccaccini AR. Sol-gel processing of bioactive glass nanoparticles: a review. *Adv Colloid Interface Sci*. 2017;249:363–73.
 99. Brühwiler D. Postsynthetic functionalization of mesoporous silica. *Nanoscale*. 2010;2(6):887–92.
 100. Watermann A, Brieger J. Mesoporous silica nanoparticles as drug delivery vehicles in cancer. *Nanomaterials*. 2017;7(7):189.
 101. Slowing I, Viveroescoto J, Wu C, Lin V. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. *Adv Drug Deliv Rev*. 2008;60(11):1278–88.
 102. Perez RA, Singh RK, Kim T-H, Kim H-W. Silica-based multifunctional nanodelivery systems toward regenerative medicine. *Mater Horizons*. 2017;4(5):772–99.
 103. Sui B, Liu X, Sun J. Dual-functional dendritic mesoporous bioactive glass nanospheres for calcium influx-mediated specific tumor suppression and controlled drug delivery in vivo. *ACS Appl Mater Interfaces*. 2018;10(28):23548–59.
 104. Ningsih HS, Chen L-Gu, Chung R-J, Chou Yu-J. An investigation on spray-granulated, macroporous, bioactive glass microspheres for a controlled drug delivery system. *Materials (Basel)*. 2021;14(11):3112.
 105. Sharifi E, Bigham A, Yousefiasl S, Trovato M, Ghomi M, Esmaeili Y, et al. Mesoporous bioactive glasses in cancer diagnosis and therapy: stimuli-responsive, toxicity, immunogenicity, and clinical translation. *Adv Sci*. 2022;9:2102678.
 106. Garg S, Thakur S, Gupta A, Kaur G, Pandey OP. Antibacterial and anticancerous drug loading kinetics for (10-x) CuO-xZnO-20CaO-60SiO₂-10P₂O₅ (2 ≤ x ≤ 8) mesoporous bioactive glasses. *J Mater Sci – Mater Med*. 2017;28(1):1–14.
 107. Wang X, Zhang Y, Ma Y, Chen D, Yang H, Li M. Selenium-containing mesoporous bioactive glass particles: physicochemical and drug delivery properties. *Ceram Int*. 2016;42(2):3609–17.
 108. Bains R, Sharma P, Mir RA, Jeet S, Kaur G, Pandey OP. Influence of CuO/MgO ratio on the gene expression, cytocompatibility, and antibacterial/anticancerous/analgesic drug loading kinetics for (15-x) CuO-xMgO-10P₂O₅-60SiO₂-10CaO-5ZnO (2.5 ≤ x ≤ 12.5) mesoporous bioactive glasses. *J Biomed Mater Res Part A*. 2018;106(8):2116–30.
 109. Kurtuldu F, Mutlu N, Michálek M, Zheng K, Masar M, Liverani L, et al. Cerium and gallium containing mesoporous bioactive glass nanoparticles for bone regeneration: bioactivity, biocompatibility and antibacterial activity. *Mater Sci Eng, C*. 2021;124:112050.
 110. Bano S, Akhtar M, Yasir M, Salman Maqbool M, Niaz A, Wadood A, et al. Synthesis and characterization of silver-strontium (Ag-Sr)-doped mesoporous bioactive glass nanoparticles. *Gels*. 2021;7(2):34.
 111. Wang Y, Wang J, Hao H, Cai M, Wang S, Ma J, et al. In vitro and in vivo mechanism of bone tumor inhibition by selenium-doped bone mineral nanoparticles. *ACS Nano*. 2016;10(11):9927–37.
 112. Zheng K, Sui B, Ilyas K, Boccaccini AR. Porous bioactive glass micro- and nanospheres with controlled morphology: developments, properties and emerging biomedical applications. *Mater Horiz*. 2021;8(2):300–35.
 113. Kaya S, Cresswell M, Boccaccini AR. Mesoporous silica-based bioactive glasses for antibiotic-free antibacterial applications. *Mater Sci Eng, C*. 2018;83:99–107.
 114. Iqbal S, Fakhar-E-Alam M, Akbar F, Shafiq M, Atif M, Amin N, et al. Application of silver oxide nanoparticles for the treatment of cancer. *J Mol Struct*. 2019;1189:203–9.
 115. Al-Sheddi ES, Farshori NN, Al-Oqail MM, Al-Massarani SM, Saquib Q, Wahab R, et al. Anticancer potential of green synthesized silver nanoparticles using extract of *Nepeta deflersiana* against human cervical cancer cells (HeLa). *Bioinorg Chem Appl*. 2018;2018:1–12.
 116. Kargozar S, Montazerian M, Hamzehlou S, Kim H-W, Baino F. Mesoporous bioactive glasses: promising platforms for antibacterial strategies. *Acta Biomater*. 2018;81:1–19.
 117. Chen S, Greasley SL, Ong ZY, Naruphontjirakul P, Page SJ, Hanna JV, et al. Biodegradable zinc-containing mesoporous silica nanoparticles for cancer therapy. *Mater Today Adv*. 2020;6:100066.

118. Zununi Vahed S, Salehi R, Davaran S, Sharifi S. Liposome-based drug co-delivery systems in cancer cells. *Mater Sci Eng, C*. 2017;71:1327–41.
119. Wang X, Li X, Ito A, Sogo Yu, Watanabe Y, Tsuji NM, et al. Biodegradable metal ion-doped mesoporous silica nanospheres stimulate anticancer Th1 immune response in vivo. *ACS Appl Mater Interfaces*. 2017;9(50):43538–44.
120. Fei W, Zhang Y, Ye Y, Li C, Yao Y, Zhang M, et al. Bioactive metal-containing nanomaterials for ferroptotic cancer therapy. *J Mater Chem B*. 2020;8(46):10461–73.
121. Wang F, Zhai D, Wu C, Chang J. Multifunctional mesoporous bioactive glass/upconversion nanoparticle nanocomposites with strong red emission to monitor drug delivery and stimulate osteogenic differentiation of stem cells. *Nano Res*. 2016;9(4):1193–208.
122. El-Fiqi A, Kim H-W. Sol-gel synthesis and characterization of novel cobalt ions-containing mesoporous bioactive glass nanospheres as hypoxia and ferroptosis-inducing nanotherapeutics. *J Non-Cryst Solids*. 2021;569:120999.
123. De Laia AGS, Barrioni BR, Valverde TM, De Goes AM, De Sá MA, Pereira MDeM. Therapeutic cobalt ion incorporated in poly(vinyl alcohol)/bioactive glass scaffolds for tissue engineering. *J Mater Sci*. 2020;55(20):8710–27.
124. Deng Z, Lin B, Jiang Z, Huang W, Li J, Zeng X, et al. Hypoxia-mimicking cobalt-doped borosilicate bioactive glass scaffolds with enhanced angiogenic and osteogenic capacity for bone regeneration. *Int J Biol Sci*. 2019;15(6):1113–24.
125. Fraisl P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism. *Dev Cell*. 2009;16(2):167–79.
126. Laia AGS, Valverde TM, Barrioni BR, Cunha PDaS, Goes AM, Miranda MC, et al. Cobalt-containing bioactive glass mimics vascular endothelial growth factor A and hypoxia inducible factor 1 function. *J Biomed Mater Res Part A*. 2021;109(7):1051–64.
127. Wu C, Zhou Y, Fan W, Han P, Chang J, Yuen J, et al. Hypoxia-mimicking mesoporous bioactive glass scaffolds with controllable cobalt ion release for bone tissue engineering. *Biomaterials*. 2012;33(7):2076–85.
128. Solanki AK, Lali FV, Autefage H, Agarwal S, Nommeots-Nomm A, Metcalfe AD, et al. Bioactive glasses and electrospun composites that release cobalt to stimulate the HIF pathway for wound healing applications. *Biomater Res*. 2021;25(1):1–16.
129. Azevedo MM, Jell G, O'donnell MD, Law RV, Hill RG, Stevens MM. Synthesis and characterization of hypoxia-mimicking bioactive glasses for skeletal regeneration. *J Mater Chem*. 2010;20(40):8854–64.
130. Liu G, Wang X, Zhou X, Zhang L, Mi J, Shan Z, et al. Modulating the cobalt dose range to manipulate multisystem cooperation in bone environment: a strategy to resolve the controversies about cobalt use for orthopedic applications. *Theranostics*. 2020;10(3):1074–89.
131. Perez RA, Kim J-H, Buitrago JO, Wall IB, Kim H-W. Novel therapeutic core-shell hydrogel scaffolds with sequential delivery of cobalt and bone morphogenetic protein-2 for synergistic bone regeneration. *Acta Biomater*. 2015;23:295–308.
132. Hoppe A, Jokic B, Janackovic D, Fey T, Greil P, Romeis S, et al. Cobalt-releasing 1393 bioactive glass-derived scaffolds for bone tissue engineering applications. *ACS Appl Mater Interfaces*. 2014;6(4):2865–77.
133. Anissian L, Stark A, Dahlstrand H, Granberg B, Good V, Bucht E. Cobalt ions influence proliferation and function of human osteoblast-like cells. *Acta Orthop Scand*. 2002;73(3):369–74.
134. Littmann E, Autefage H, Solanki AK, Kallepitis C, Jones JR, Alini M, et al. Cobalt-containing bioactive glasses reduce human mesenchymal stem cell chondrogenic differentiation despite HIF-1 α stabilisation. *J Eur Ceram Soc*. 2018;38(3):877–86.
135. Barrioni BR, Laia AGSDe, Valverde TM, Martins TMDaM, Caliar MV, Sá MADe, et al. Evaluation of in vitro and in vivo biocompatibility and structure of cobalt-releasing sol-gel bioactive glass. *Ceram Int*. 2018;44(16):20337–47.
136. Fleury C, Petit A, Mwale F, Antoniou J, Zukor DJ, Tabrizian M, et al. Effect of cobalt and chromium ions on human MG-63 osteoblasts in vitro: morphology, cytotoxicity, and oxidative stress. *Biomaterials*. 2006;27(18):3351–60.
137. Azevedo MM, Tsigkou O, Nair R, Jones JR, Jell G, Stevens MM. Hypoxia inducible factor-stabilizing bioactive glasses for directing mesenchymal stem cell behavior. *Tissue Eng, A*. 2015;21(1–2):382–9.
138. Liu J, Zou T, Yao Q, Zhang Y, Zhao Yi, Zhang C. Hypoxia-mimicking cobalt-doped multi-walled carbon nanotube nanocomposites enhance the angiogenic capacity of stem cells from apical papilla. *Mater Sci Eng, C*. 2021;120:111797.
139. El-Fiqi A, Kim H-W. Iron ions-releasing mesoporous bioactive glass ultrasmall nanoparticles designed as ferroptosis-based bone cancer nanotherapeutics: ultrasonic-coupled sol-gel synthesis, properties and iron ions release. *Mater Lett*. 2021;294:129759.
140. Moorhouse CP, Halliwell B, Grootveld M, Gutteridge JMC. Cobalt(II) ion as a promoter of hydroxyl radical and possible 'crypto-hydroxyl' radical formation under physiological conditions. Differential effects of hydroxyl radical scavengers. *Biochim Biophys Acta (BBA)—Gen Subj*. 1985;843(3):261–8.
141. Yamamoto K, Inoue S, Yamazaki A, Yoshinaga T, Kawanishi S. Site-specific DNA damage induced by cobalt(II) ion and hydrogen peroxide: role of singlet oxygen. *Chem Res Toxicol*. 1989;2(4):234–9.
142. Zhao L, Li J, Li Y, Liu J, Wirth T, Li Z. Selenium-containing naphthalimides as anticancer agents: design, synthesis and bioactivity. *Bioorg Med Chem*. 2012;20(8):2558–63.
143. Rana KS, Souza LPDe, Isaacs MA, Raja FNS, Morrell AP, Martin RA. Development and characterization of gallium-doped bioactive glasses for potential bone cancer applications. *ACS Biomater Sci Eng*. 2017;3(12):3425–32.
144. Singh RK, El-Fiqi AM, Patel KD, Kim H-W. A novel preparation of magnetic hydroxyapatite nanotubes. *Mater Lett*. 2012;75:130–3.
145. Wang S, Luo J, Zhang Z, Dong D, Shen Y, Fang Y, et al. Iron and magnetic: new research direction of the ferroptosis-based cancer therapy. *Am J Cancer Res*. 2018;8(10):1933.
146. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. *Nat Rev Cancer*. 2014;14(3):199–208.
147. Wang L, Long NJ, Lihua Li, Lu Y, Li M, Cao J, et al. Multi-functional bismuth-doped bioglasses: combining bioactivity

- and photothermal response for bone tumor treatment and tissue repair. *Light Sci Appl*. 2018;7(1):1–13.
148. Singh RK, Kurian AG, Patel KD, Mandakhbayar N, Lee Na-H, Knowles JC, et al. Label-free fluorescent mesoporous bioglass for drug delivery, optical triple-mode imaging, and photothermal/photodynamic synergistic cancer therapy. *ACS Appl Bio Mater*. 2020;3(4):2218–29.
 149. Kargozar S, Mozafari M, Ghodrati S, Fiume E, Baino F. Copper-containing bioactive glasses and glass-ceramics: from tissue regeneration to cancer therapeutic strategies. *Mater Sci Eng, C*. 2021;121:111741.
 150. Chang L, Liu Y, Wu C. Copper-doped mesoporous bioactive glass for photothermal enhanced chemotherapy. *J Biomed Nanotechnol*. 2018;14(4):786–94.
 151. Yang Q, Yin H, Xu T, Zhu D, Yin J, Chen Y, et al. Engineering 2D mesoporous silica@MXene-integrated 3D-printing scaffolds for combinatory osteosarcoma therapy and NO-augmented bone regeneration. *Small*. 2020;16(14):1906814.
 152. Mahmoudi K, Bouras A, Bozec D, Ivkov R, Hadjipanayis C. Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans. *Int J Hyperthermia*. 2018;34(8):1316–28.
 153. Christophi C, Winkworth A, Muralidharan V, Evans P. The treatment of malignancy by hyperthermia. *Surg Oncol*. 1998;7(1–2):83–90.
 154. Hildebrandt B. The cellular and molecular basis of hyperthermia. *Crit Rev Oncol Hematol*. 2002;43(1):33–56.
 155. Kargozar S, Mozafari M, Hamzehlou S, Kim H-W, Baino F. Mesoporous bioactive glasses (MBGs) in cancer therapy: full of hope and promise. *Mater Lett*. 2019;251:241–6.
 156. Baino F, Fiume E, Miola M, Leone F, Onida B, Laviano F, et al. Fe-doped sol-gel glasses and glass-ceramics for magnetic hyperthermia. *Materials (Basel)*. 2018;11(1):173.
 157. Bigham A, Aghajanian AH, Allahdaneh S, Hassanzadeh-Tabrizi SA. Multifunctional mesoporous magnetic Mg₂SiO₄-CuFe₂O₄ core-shell nanocomposite for simultaneous bone cancer therapy and regeneration. *Ceram Int*. 2019;45(15):19481–8.
 158. Li X, Wang X, Hua Z, Shi J. One-pot synthesis of magnetic and mesoporous bioactive glass composites and their sustained drug release property. *Acta Mater*. 2008;56(13):3260–5.
 159. Miola M, Bruno M, Gerbaldo R, Laviano F, Vernè E. Melt-derived copper-doped ferrimagnetic glass-ceramic for tumor treatment. *Ceram Int*. 2021;47:31749–55.
 160. Abdel-Hameed SAM, Elwan RL. Effect of La₂O₃, CoO, Cr₂O₃ and MoO₃ nucleating agents on crystallization behavior and magnetic properties of ferromagnetic glass-ceramic in the system Fe₂O₃·CaO·ZnO·SiO₂. *Mater Res Bull*. 2012;47(5):1233–8.
 161. Singh RK, Kothiyal GP, Srinivasan A. Magnetic and structural properties of CaO-SiO₂-P₂O₅-Na₂O-Fe₂O₃ glass ceramics. *J Magn Magn Mater*. 2008;320(7):1352–6.
 162. Leenakul W, Kantha P, Pisitpipathsin N, Rujijjanagul G, Eitssayeam S, Pengpat K. Structural and magnetic properties of SiO₂-CaO-Na₂O-P₂O₅ containing BaO-Fe₂O₃ glass-ceramics. *J Magn Magn Mater*. 2013;325:102–6.
 163. Bretcanu O, Vernè E, Cöisson M, Tiberto P, Allia P. Magnetic properties of the ferrimagnetic glass-ceramics for hyperthermia. *J Magn Magn Mater*. 2006;305(2):529–33.
 164. Kothiyal GP, Sharma K, Dixit A, Srinivasan A. Structural and magnetic studies on nano-crystalline biocompatible glass/glass-ceramic. *AIP Conf Proc*. 2010;1313(1):55–9.
 165. Hsi C-S, Cheng H-Z, Hsu H-J, Chen Y-S, Wang M-C. Crystallization kinetics and magnetic properties of iron oxide contained 25Li₂O-8MnO₂-20CaO-2P₂O₅-45SiO₂ glasses. *J Eur Ceram Soc*. 2007;27(10):3171–6.
 166. Abdel-Hameed SAM, Margha FH, Ouis MA. Effect of CeO₂ on the crystallization behavior and magnetic properties of Zn-ferrite glass ceramics. *J Alloys Compd*. 2013;554:371–7.
 167. Shah SA, Hashmi MU, Alam S. Effect of aligning magnetic field on the magnetic and calorimetric properties of ferrimagnetic bioactive glass ceramics for the hyperthermia treatment of cancer. *Mater Sci Eng, C*. 2011;31(5):1010–6.
 168. Abdel-Hameed SAM, El Kady AM. Effect of different additions on the crystallization behavior and magnetic properties of magnetic glass-ceramic in the system Fe₂O₃-ZnO-CaO-SiO₂. *J Adv Res*. 2012;3(2):167–75.
 169. Mortazavi SR, Karimzadeh F, Emadi R, Ahmadvand H. Synthesis and evaluation of a glass-ceramic system containing zinc ferrite nanocrystals. *J Non-Cryst Solids*. 2021;559:120704.
 170. Singh RK, Srinivasan A. EPR and magnetic properties of MgO-CaO-SiO₂-P₂O₅-CaF₂-Fe₂O₃ glass-ceramics. *J Magn Magn Mater*. 2009;321(18):2749–52.
 171. Singh RK, Srinivasan A. Bioactivity of ferrimagnetic MgO-CaO-SiO₂-P₂O₅-Fe₂O₃ glass-ceramics. *Ceram Int*. 2010;36(1):283–90.
 172. Abdel-Hameed SAM, Marzouk MA, Farag MM. Effect of P₂O₅ and MnO₂ on crystallization of magnetic glass ceramics. *J Adv Res*. 2014;5(5):543–50.
 173. Intawin P, Leenakul W, Jantaratana P, Munkpakdee A, Pengpat K. Fabrication of SrFe₁₂O₁₉-P₂O₅-CaO-Na₂O bioactive glass-ceramics at various sintering temperatures. *Ferroelectrics*. 2015;489(1):35–42.
 174. Danewalia SS, Kaur S, Bansal N, Khan S, Singh K. Influence of TiO₂ and thermal processing on morphological, structural and magnetic properties of Fe₂O₃/MnO₂ modified glass-ceramics. *J Non-Cryst Solids*. 2019;513:64–9.
 175. Hou Y, Zhang G-H, Chou K-C. Effect of atmosphere control on magnetic properties of CaO-Al₂O₃-SiO₂-Fe₃O₄ glass ceramics. *J Eur Ceram Soc*. 2021;41(4):2663–73.
 176. Wójcik NA, Tagiara NS, Ali S, Górnicka K, Segawa H, Klimczuk T, et al. Structure and magnetic properties of BeO-Fe₂O₃-Al₂O₃-TeO₂ glass-ceramic composites. *J Eur Ceram Soc*. 2021;41(10):5214–22.
 177. Khomeini M, Hesaraki S, Kolahi A. Effect of BaO substitution for CaO on the structural and thermal properties of SiO₂-B₂O₃-Al₂O₃-CaO-Na₂O-P₂O₅ bioactive glass system used for implant coating applications. *Ceram Int*. 2021;47:31666–80.
 178. Baino F, Fiume E, Miola M, Leone F, Onida B, Vernè E. Fe-doped bioactive glass-derived scaffolds produced by sol-gel foaming. *Mater Lett*. 2019;235:207–11.
 179. Sepulveda P, Jones JR, Hench LL. Characterization of melt-derived 45S5 and sol-gel-derived 58S bioactive glasses. *J Biomed Mater Res*. 2001;58(6):734–40.
 180. Sepulveda P, Jones JR, Hench LL. In vitro dissolution of melt-derived 45S5 and sol-gel derived 58S bioactive glasses. *J Biomed Mater Res*. 2002;61(2):301–11.

181. Izquierdo-Barba I, Vallet-Regí M. Mesoporous bioactive glasses: relevance of their porous structure compared to that of classical bioglasses. *Biomed Glass*. 2015;1(1):140–50.
182. Fiume E, Migneco C, Verné E, Baino F. Comparison between bioactive sol-gel and melt-derived glasses/glass-ceramics based on the multicomponent $\text{SiO}_2\text{-P}_2\text{O}_5\text{-CaO-MgO-Na}_2\text{O-K}_2\text{O}$ system. *Materials (Basel)*. 2020;13(3):540.
183. Qin X, Ji L, Zheng J, Shi G, Dunham RE, Yao H, Zhu A. A general strategy for preparing porous metal-doped bioactive glass fibers. *Mater Lett*. 2021;290:129509.
184. Dittler ML, Zelis PM, Beltrán AM, Destch R, Grillo CA, Gonzalez MC, et al. Magnetic 3D scaffolds for tissue engineering applications: bioactive glass (45S5) coated with iron-loaded hydroxyapatite nanoparticles. *Biomed Mater*. 2021;16(5):055006.
185. Zhang J, Zhao S, Zhu M, Zhu Y, Zhang Y, Liu Z, Zhang C. 3D-printed magnetic $\text{Fe}_3\text{O}_4/\text{MBG}/\text{PCL}$ composite scaffolds with multifunctionality of bone regeneration, local anticancer drug delivery and hyperthermia. *J Mater Chem B*. 2(43):2014;7583–95.
186. Li G, Zhang K, Pei Z, Zhang N, Yu Y, Zhao S, et al. A novel method to enhance magnetic property of bioactive glass-ceramics for hyperthermia. *Ceram Int*. 2019;45(4):4945–56.
187. Borges R, Mendonça-Ferreira L, Rettori C, Pereira ISO, Baino F, Marchi J. New sol-gel-derived magnetic bioactive glass-ceramics containing superparamagnetic hematite nanocrystals for hyperthermia application. *Mater Sci Eng, C*. 2021;120:111692.
188. Wang YY, Li B, Luo WQ, Cao F. Bioactivity of $\text{Fe}_2\text{O}_3\text{-CaO-SiO}_2$ glass ceramics modified through the addition of P_2O_5 and TiO_2 . *Ceram Int*. 2017;43(9):6738–45.
189. Yazdanpanah A, Moztafzadeh F, Arabyazdi S. A heat-generating lithium-ferrite doped bioactive glass for cancer hyperthermia. *Phys B Condens Matter*. 2020;593:412298.
190. Koohkan R, Hooshmand T, Mohebbi-Kalhari D, Tahriri M, Marefati MT. Synthesis, characterization, and in vitro biological evaluation of copper-containing magnetic bioactive glasses for hyperthermia in bone defect treatment. *ACS Biomater Sci Eng*. 2018;4(5):1797–811.
191. Zhang P, Pu Y, Wu Y, Zhao J, Luo Y. Influence of Replacement of B_2O_3 by SiO_2 on the structure and magnetic properties of $\text{BaO-Fe}_2\text{O}_3\text{-SiO}_2\text{-B}_2\text{O}_3\text{-CeO}_2$ glass-ceramics. *J Supercond Novel Magn*. 2016;29(6):1557–60.
192. Verné E, Vitale-Brovarone C, Baino F. Anticancer drugs grafting to a bioactive and ferrimagnetic glass-ceramic. *J Appl Biomater Biomech*. 2010;8(2):131.
193. Dabbagh A, Hedayatnasab Z, Karimian H, Sarraf M, Yeong CH, Madaah Hosseini HR, et al. Polyethylene glycol-coated porous magnetic nanoparticles for targeted delivery of chemotherapeutics under magnetic hyperthermia condition. *Int J Hyperthermia*. 2019;36(1):104–14.
194. Baino F, Novajra G, Miguez-Pacheco V, Boccaccini AR, Vitale-Brovarone C. Bioactive glasses: special applications outside the skeletal system. *J Non-Cryst Solids*. 2016;432:15–30.
195. Jiang Y, Ou J, Zhang Z, Qin Q-H. Preparation of magnetic and bioactive calcium zinc iron silicon oxide composite for hyperthermia treatment of bone cancer and repair of bone defects. *J Mater Sci – Mater Med*. 2011;22(3):721–9.
196. Zhu M, Zhang J, Zhou Y, Liu Y, He X, Tao C, et al. Preparation and characterization of magnetic mesoporous bioactive glass/carbon composite scaffolds. *J Chem*. 2013;2013:1–11.
197. Jayalekshmi AC, Victor SP, Sharma CP. Magnetic and degradable polymer/bioactive glass composite nanoparticles for biomedical applications. *Colloids Surf, B: Biointerfaces*. 2013;101:196–204.
198. Tripathi H, Pandey GC, Dubey A, Shaw SK, Prasad NK, Singh SP, et al. Superparamagnetic manganese ferrite and strontium bioactive glass nanocomposites: enhanced biocompatibility and antimicrobial properties for hyperthermia application. *Adv Eng Mater*. 2021;23(1):2000275.
199. Bruno M, Miola M, Bretcanu O, Vitale-Brovarone C, Gerbaldo R, Laviano F, et al. Composite bone cements loaded with a bioactive and ferrimagnetic glass-ceramic. Part I: Morphological, mechanical and calorimetric characterization. *J Biomater Appl*. 2014;29(2):254–67.
200. Verné E, Bruno M, Miola M, Maina G, Bianco C, Cochis A, et al. Composite bone cements loaded with a bioactive and ferrimagnetic glass-ceramic: leaching, bioactivity and cytocompatibility. *Mater Sci Eng, C*. 2015;53:95–103.
201. Kohli JT, Hubert M, Youngman RE, Morse DL. A corning perspective on the future of technical glass in our evolving world. *Int J Appl Glass Sci*. 2022;13:292–307.
202. Marzari N. The frontiers and the challenges. *Nat Mater*. 2016;15(4):381–2.
203. Boosting materials modelling. *Nat Mater*. 2016;15(4):365. <https://doi.org/10.1038/nmat4619>. PMID: 27005908.
204. Mauro JC, Tandia A, Vargheese KD, Mauro YZ, Smedskjaer MM. Accelerating the design of functional glasses through modeling. *Chem Mater*. 2016;28(12):4267–77.
205. Mauro JC. Decoding the glass genome. *Curr Opin Solid State Mater Sci*. 2018;22(2):58–64.
206. Montazerian M, Zannotto ED, Mauro JC. Model-driven design of bioactive glasses: from molecular dynamics through machine learning. *Int Mater Rev*. 2020;65(5):297–321.

How to cite this article: Moeini A, Hassanzadeh Chinijani T, Malek Khachatourian A, Vinicius Lia Fook M, Baino F, Montazerian M. A critical review of bioactive glasses and glass-ceramics in cancer therapy. *Int J Appl Glass Sci*. 2023;14:69–87. <https://doi.org/10.1111/ijag.16601>